The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures


  • Helen R. Davies
  • Dominik Glodzik
  • Sandro Morganella
  • Lucy R. Yates
  • Johan Staaf
  • Xueqing Zou
  • Manasa Ramakrishna
  • Sancha Martin
  • Sandrine Boyault
  • Anieta M. Sieuwerts
  • Peter T Simpson
  • Tari A King
  • Keiran Raine
  • Jorunn E. Eyfjord
  • Gu Kong
  • Åke Borg
  • Ewan Birney
  • Hendrik G. Stunnenberg
  • Marc J van de Vijver
  • Anne-Lise Børresen-Dale
  • John W. M. Martens
  • Paul N. Span
  • Sunil R. Lakhani
  • Anne Vincent-Salomon
  • Christos Sotiriou
  • Andrew Tutt
  • Alastair M Thompson
  • Steven Van Laere
  • Andrea L. Richardson
  • Alain Viari
  • Peter J. Campbell
  • Michael R. Stratton
  • Serena Nik-Zainal

Summary, in English

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic substitution, insertion/deletion and rearrangement patterns, or 'mutational signatures', were associated with BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency. A weighted model called HRDetect was developed to accurately detect BRCA1/BRCA2-deficient samples. HRDetect identifies BRCA1/BRCA2-deficient tumors with 98.7% sensitivity (area under the curve (AUC) = 0.98). Application of this model in a cohort of 560 individuals with breast cancer, of whom 22 were known to carry a germline BRCA1 or BRCA2 mutation, allowed us to identify an additional 22 tumors with somatic loss of BRCA1 or BRCA2 and 47 tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected. We validated HRDetect on independent cohorts of breast, ovarian and pancreatic cancers and demonstrated its efficacy in alternative sequencing strategies. Integrating all of the classes of mutational signatures thus reveals a larger proportion of individuals with breast cancer harboring BRCA1/BRCA2 deficiency (up to 22%) than hitherto appreciated (∼1-5%) who could have selective therapeutic sensitivity to PARP inhibition.


  • Breastcancer-genetics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Familial Breast Cancer

Publishing year







Nature Medicine





Document type

Journal article


Nature Publishing Group


  • Cancer and Oncology




  • Genomisk karakterisering av trippelnegativ bröstcancer (TNBC)

Research group

  • Familial Breast Cancer


  • ISSN: 1546-170X